MENS (Jyong Biotech) Owner Earnings per Share (TTM): 0.22 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MENS Jyong Biotech Ltd MENS
10 GF Score
Price $2.39
! 3 Warning Signs
View Full Analysis

What is Jyong Biotech Owner Earnings per Share (TTM)?

Jyong Biotech MENS +5.29% 10 Owner Earnings per Share (TTM) is 0.22 as of Dec. 2025. GuruFocus rates MENS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 211 Biotechnology companies, Jyong Biotech ranks better than 77.73% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Jyong Biotech's Owner Earnings per Share (TTM) ended in Dec. 2025 was $0.22. It's Price-to-Owner-Earnings ratio for today is 10.86.


The historical rank and industry rank for Jyong Biotech's Owner Earnings per Share (TTM) or its related term are showing as below:

MENS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0   Med: 0   Max: 11.16
Current: 10.93


During the past 5 years, the highest Price-to-Owner-Earnings ratio of Jyong Biotech was 11.16. The lowest was 0.00. And the median was 0.00.


MENS's Price-to-Owner-Earnings is ranked better than
77.73% of 211 companies
in the Biotechnology industry
Industry Median: 26.23 vs MENS: 10.93

Jyong Biotech's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was $-0.04. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.06. It's PE Ratio (TTM) ratio for today is At Loss.

Jyong Biotech's EPS without NRI for the six months ended in Dec. 2025 was $-0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.06. It's PE Ratio without NRI ratio for today is At Loss.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Jyong Biotech Owner Earnings per Share (TTM) Related Terms


Jyong Biotech Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Jyong Biotech's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jyong Biotech Owner Earnings per Share (TTM) Chart

Jyong Biotech Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
0.00 0.00 0.00 0.00 0.22

Jyong Biotech Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Owner Earnings per Share (TTM) Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.22

MENS vs CNTN, SPRB, CDXS: Owner Earnings per Share (TTM) Comparison

For the Biotechnology subindustry, Jyong Biotech's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jyong Biotech Price-to-Owner-Earnings vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jyong Biotech's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Jyong Biotech's Price-to-Owner-Earnings falls into.


MENS
10GF Score
Jyong Biotech Ltd MENS
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jyong Biotech Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Jyong Biotech's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income -4.67
Depreciation, Depletion and Amortization 0.10
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.19
Change In Working Capital 20.74
Shares Outstanding (Diluted Average) 73.01

1. Start with "Net Income" from income statement. Jyong Biotech's Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.67 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Jyong Biotech's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2025 was $0.10 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Jyong Biotech's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.19 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Jyong Biotech's 5-Year Average Maintenance Capital Expenditure = $0.19 Mil

5. "Change In Working Capital" is from cashflow statement. Jyong Biotech's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2025 was $20.74 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Jyong Biotech's Shares Outstanding (Diluted Average) for the months ended in Dec. 2025 was 73.011 Mil.

Jyong Biotech's Onwer Earnings Per Share for Dec. 2025 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -4.671 +0.1+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.1915+20.735)/73.011
=0.22

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=2.39/0.22
=10.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 0.22 mean?
Jyong Biotech (MENS) has a Owner Earnings per Share (TTM) of 0.22 as of Dec. 2025. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Jyong Biotech. According to the industry distribution chart, Jyong Biotech ranks #47 out of 211 companies in the Biotechnology industry, placing it in the top 22.3%.
Is Jyong Biotech's Owner Earnings per Share (TTM) too high?
Jyong Biotech's current Owner Earnings per Share (TTM) is 0.22. The Biotechnology industry median Owner Earnings per Share (TTM) is 26.23. Jyong Biotech's value of 0.22 is 99.2% below this industry median. Based on the distribution chart, Jyong Biotech ranks #47 out of 211 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jyong Biotech has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Jyong Biotech's Owner Earnings per Share (TTM) compare to CNTN and SPRB?
According to the Biotechnology industry distribution chart, Jyong Biotech ranks #47 out of 211 companies for Owner Earnings per Share (TTM). This places Jyong Biotech in the top 22% of its industry — outperforming the majority of peers. The industry median Owner Earnings per Share (TTM) is 26.23. Jyong Biotech's value of 0.22 is 99.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Biotechnology company?
The median Owner Earnings per Share (TTM) among Biotechnology companies is 26.23, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jyong Biotech's current Owner Earnings per Share (TTM) of 0.22 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Jyong Biotech. For the Biotechnology industry, the median Owner Earnings per Share (TTM) is 26.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jyong Biotech's current Owner Earnings per Share (TTM) is 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jyong Biotech stock overvalued right now?
Jyong Biotech (MENS) has a current Owner Earnings per Share (TTM) of 0.22. The current Owner Earnings per Share (TTM) is 0.22 and 99.2% below the Biotechnology industry median of 26.23. Jyong Biotech's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Jyong Biotech (MENS), the current Owner Earnings per Share (TTM) is 0.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jyong Biotech Business Description

Address Xintai 5th Road, 23F-3, No. 95, Section 1, Xizhi district, New Taipei, TWN, 221
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
10GF Score

Get the complete analysis for MENS

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.39
Price